Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
IconOVir Bio is a preclinical-stage biotechnology company developing oncolytic virus therapy for the treatment of patients with cancer.
Festicket is a marketplace to discover and book music festival tickets, accommodation, transfers and extras.
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
import.io offers a Web Data Integration solution that provides global businesses with high-quality, scalable data from the web.
The workflow optimization platform for commercial real estate professionals
EyeEm builds technology to showcase the best images from the world’s leading photo community.
Atopix Therapeutics Limited is a privately held, clinical-stage, biopharmaceutical company based in Oxford, UK
Rigontec is the leader in RIG-I targeting RNA therapeutics developing novel immuno-oncology treatment options.
YPlan uncover the best events every day so you can get out and Live Your City.
ImevaX is a biopharmaceutical company founded in 2014 based in Munich, Germany
Sapiens is a medical device company that delivers solutions for deep brain stimulation therapy.
Wellington Partners has invested in 59 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Wellington Partners's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, E-Commerce. The firm invests across 30 different industry categories.
Among tracked funding rounds, IconOVir Bio received $77.0M in a Series A round. Wellington Partners's total known invested capital is $2.1B.
Wellington Partners's average investment size is $41.5M across its portfolio of 59 companies.
Recent Wellington Partners portfolio additions include IconOVir Bio, Festicket. These companies were founded in 2020 or later.